WO2021231931A8 - Methods of treating sars-cov-2 infections - Google Patents

Methods of treating sars-cov-2 infections Download PDF

Info

Publication number
WO2021231931A8
WO2021231931A8 PCT/US2021/032557 US2021032557W WO2021231931A8 WO 2021231931 A8 WO2021231931 A8 WO 2021231931A8 US 2021032557 W US2021032557 W US 2021032557W WO 2021231931 A8 WO2021231931 A8 WO 2021231931A8
Authority
WO
WIPO (PCT)
Prior art keywords
cov
infections
methods
treating sars
sars
Prior art date
Application number
PCT/US2021/032557
Other languages
French (fr)
Other versions
WO2021231931A1 (en
Inventor
Steven Hoffman
John Rothman
Original Assignee
Tyme, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tyme, Inc. filed Critical Tyme, Inc.
Publication of WO2021231931A1 publication Critical patent/WO2021231931A1/en
Publication of WO2021231931A8 publication Critical patent/WO2021231931A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N45/00—Biocides, pest repellants or attractants, or plant growth regulators, containing compounds having three or more carbocyclic rings condensed among themselves, at least one ring not being a six-membered ring
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dentistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The disclosure is directed to methods of using UDCA, or a pharmaceutically acceptable salt thereof, or a derivative thereof, for the treatment of SARS-CoV-2 infections.
PCT/US2021/032557 2020-05-14 2021-05-14 Methods of treating sars-cov-2 infections WO2021231931A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063024541P 2020-05-14 2020-05-14
US63/024,541 2020-05-14
US202063060770P 2020-08-04 2020-08-04
US63/060,770 2020-08-04

Publications (2)

Publication Number Publication Date
WO2021231931A1 WO2021231931A1 (en) 2021-11-18
WO2021231931A8 true WO2021231931A8 (en) 2022-01-20

Family

ID=78525089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/032557 WO2021231931A1 (en) 2020-05-14 2021-05-14 Methods of treating sars-cov-2 infections

Country Status (1)

Country Link
WO (1) WO2021231931A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013901A (en) 2019-05-14 2022-04-12 Tyme Inc Compositions and methods for treating cancer.
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
WO2024120452A1 (en) * 2022-12-07 2024-06-13 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods for prophylaxis and treatment of covid-19

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8706313D0 (en) * 1987-03-17 1987-04-23 Health Lab Service Board Treatment & prevention of viral infections
AU2540397A (en) * 1996-03-22 1997-10-10 Mayo Foundation For Medical Education And Research Combinations of an ursodeoxycholic acid compound and a nsaid for the chemopreventive protection of the colorectum
US9198965B2 (en) * 2008-06-13 2015-12-01 Wisconsin Alumni Research Foundation Peptide adjuvant for influenza vaccination

Also Published As

Publication number Publication date
WO2021231931A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
WO2021231931A8 (en) Methods of treating sars-cov-2 infections
EP4331677A3 (en) Methods of treating feline coronavirus infections
MX2022006663A (en) Oxygen-containing heterocyclic compound, preparation method and application thereof.
WO2021147236A9 (en) Use of substituted aminopropionate compound in treatment of sars-cov-2 infections
MX2023001876A (en) Rapamycin derivatives.
MX2021010122A (en) Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders.
CA3156303A1 (en) 5-fluoronicotinamide derivatives and uses thereof
CA3013473C (en) Methods for treatment and prophylaxis of hiv and aids
MX2021007247A (en) Rapamycin derivatives.
MX2023001071A (en) Treatment of migraine.
MX2020008816A (en) Triazine derivatives for treating diseases relating to neurotrophins.
WO2020201833A8 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
MX2021012105A (en) Pyrrole compounds.
MX2019006612A (en) IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS.
MX2024003952A (en) Combination comprising atogepant for treating migraine.
MX2021007258A (en) Amorphous sparsentan compositions.
WO2022115381A8 (en) Compositions and methods for treating cns disorders
PH12018500202B1 (en) New effective aminoglycoside antibiotic for multidrug-resistant bacteria
MX2020002630A (en) IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS.
WO2023081830A3 (en) Compositions and treatments with nirogacestat
SA521431048B1 (en) Pyrrolidine Compounds
WO2022015823A3 (en) Methods for screening novel coronavirus antivirals and methods of using antivirals for the treatment of coronavirus infections
EP4114393A4 (en) Methods for the treatment and prevention of lung infections by administration of tafenoquine
MX2022004912A (en) Novel substituted condensed ring compound.
NZ737820A (en) Mannose derivatives for treating bacterial infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21804803

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21804803

Country of ref document: EP

Kind code of ref document: A1